Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · Real-Time Price · USD
18.57
-0.66 (-3.41%)
At close: Aug 25, 2025, 4:00 PM
18.50
-0.07 (-0.38%)
After-hours: Aug 25, 2025, 4:43 PM EDT
-3.41%
Market Cap1.52B
Revenue (ttm)305,000
Net Income (ttm)-275.74M
Shares Out 81.66M
EPS (ttm)-3.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume759,794
Open19.23
Previous Close19.23
Day's Range18.54 - 19.73
52-Week Range9.90 - 27.20
Beta0.48
AnalystsStrong Buy
Price Target38.80 (+108.94%)
Earnings DateAug 6, 2025

About VRDN

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of e... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 143
Stock Exchange NASDAQ
Ticker Symbol VRDN
Full Company Profile

Financial Performance

In 2024, Viridian Therapeutics's revenue was $302,000, a decrease of -3.82% compared to the previous year's $314,000. Losses were -$208.56 million, 19.2% more than in 2023.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price target is $38.8, which is an increase of 108.94% from the latest price.

Price Target
$38.8
(108.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results

Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday.

18 days ago - Benzinga

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...

19 days ago - Business Wire

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

21 days ago - Business Wire

Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

26 days ago - Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

7 weeks ago - Business Wire

Viridian Therapeutics: The Song Remains The Same

Viridian Therapeutics is targeting thyroid eye disease with late-stage assets, and shares have dropped significantly over the past six months, despite no major negative news. Analyst sentiment remains...

2 months ago - Seeking Alpha

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

3 months ago - Business Wire

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

3 months ago - Business Wire

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...

3 months ago - Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...

3 months ago - Business Wire

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

5 months ago - Business Wire

Viridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year Window

Viridian Therapeutics' VRDN-001 shows promising data in treating Thyroid Eye Disease (TED), with strong proptosis and diplopia resolution rates, rivaling Amgen's Tepezza. Positive results from Thrive ...

6 months ago - Seeking Alpha

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for seriou...

6 months ago - Business Wire

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

8 months ago - Business Wire

Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)

Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing...

8 months ago - Seeking Alpha

Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation

Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of differentiation to T...

8 months ago - Seeking Alpha

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade)

Viridian Therapeutics, Inc.'s stock surged over 20% after key trial results came out before the bell on Monday. The study results triggered a rash of buy reissuances from analyst firms and improved th...

8 months ago - Seeking Alpha

Viridian Therapeutics' eye disorder drug meets late-stage study goal

Viridian Therapeutics said on Monday its experimental drug to treat an immune system disorder, chronic thyroid eye disease, met the main goal of a late-stage study.

9 months ago - Reuters

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

9 months ago - Business Wire

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...

9 months ago - Business Wire

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

10 months ago - Business Wire

Viridian Therapeutics' Superior Prospects Make It A Buy

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 a...

10 months ago - Seeking Alpha

3 Small Biotech Stocks With The 'Big Mo' Right Now

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong mome...

Other symbols: AUPHCORT
1 year ago - Seeking Alpha

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...

1 year ago - Business Wire

Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way

Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for TH...

1 year ago - Seeking Alpha